Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 12c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.36), $0.12 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $83.27 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
• Boeing wins $121 million Navy contract for P-8A upgrades